Skip to content

Assessment of Lipid Profile in Juvenile Systemic Lupus Erythematosus

Assessment of Lipid Profile in Juvenile Systemic Lupus Erythematosus

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06151990
Enrollment
102
Registered
2023-11-30
Start date
2023-12-31
Completion date
2025-10-31
Last updated
2023-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus

Brief summary

. To determine pattern and frequency of dyslipoproteinemia in patients with newly diagnosed juvenile SLE and to assess effect of disease activity on lipid profile of patients with juvenile SLE.

Detailed description

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem inflammation and the presence of circulating autoantibodies against self-antigens leading to inflammatory damage of many target organs including the skin, joints, kidneys, blood cells, blood vessels, and the central nervous system.Premature atherosclerosis has been recognized as an important issue for patients with SLE since the mid-1970s. Among the traditional risk factors of atherosclerosis, a history of smoking, diabetes, hypertension, and abnormal lipid profile have been shown to be important (7). In patients with juvenile SLE, smoking, diabetes, and uncontrolled hypertension are not common and therefore abnormal lipid profiles may be the most important risk factor.The lipid profile of both children and adults with SLE is the result of a combination of the influences of active disease, therapies, and genetics. The best way to determine the maximal potential effect of disease activity itself would be to examine patients at the time of presentation of SLE, when they are likely to have high disease activity but no effect of corticosteroid therapy.Studies in patients with active SLE suggested that there is a distinct pattern of lipid abnormalities of increased very low-density lipoprotein (VLDL) and triglycerides and decreased high-density lipoprotein (HDL-C), cholesterol and apolipoprotein A1 levels (active SLE pattern)

Interventions

OTHERlipid profile

Measurements for CHOL,TG,LDL-C and HDL-C obtained following an overnight fasting

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
5 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

1. Patients who are diagnosed according to 2019 European League against Rheumatism (EULAR) /American College of Rheumatology (ACR) SLE classification criteria . 2. Patients diagnosed with jSLE between 5 and 18 years of age

Exclusion criteria

* 1\. Patients on lipid lowering drugs for any other reason. 2. Patients with other autoimmune disease.

Design outcomes

Primary

MeasureTime frameDescription
lipid profile2 yearspattern and frequency of dyslipoproteinemia in patients with newly diagnosed JSLE .

Countries

Egypt

Contacts

Primary ContactSara A Mahmoud, resident
saraabdelnassermahmoud1997@gmail.com+02-01144250777
Backup ContactJaafar I Mohamad, professor
Gafaribrahim2015@aun.edu.eg+02-01020627864

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026